Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALLO-819
- Development stage
- Preclinical
- Lead developer
- Allogene Therapeutics
- Modality
- Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ALLO-819 is an investigational allogeneic chimeric antigen receptor T cell (CAR T) therapy that targets fms-like tyrosine kinase 3 (FLT3/CD135), a receptor overexpressed in acute myeloid leukemia (AML) cells. It is manufactured by gene-editing healthy donor T cells to express an anti-FLT3 CAR and engineered to knock out T cell receptor alpha chain (TRAC) and CD52 loci using TALEN technology, minimizing the risk of graft-versus-host disease (GvHD) and rendering the therapy resistant to anti-CD52 antibody-mediated lymphodepletion. ALLO-819 includes a safety "off-switch" via a rituximab-inducible mechanism, allowing for selective depletion of the infused CAR T cells if necessary. Preclinical models confirmed anti-leukemic efficacy, high specificity for FLT3, limited off-target toxicity outside hematopoietic tissue, and CAR T cell inactivation by rituximab, supporting its advancement for the treatment of AML[1][2][3][5][6][8][9][10].
- Brand names
- ALLO-819ALLO819ALLO 819
- Other names
- ALLO-819ALLO819ALLO 819
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on ALLO-819.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALLO-819.